Jeffrey Alan Hawkins Sells 11,311 Shares of Quantum-Si (NASDAQ:QSI) Stock

Quantum-Si Incorporated (NASDAQ:QSI) CEO Jeffrey Alan Hawkins sold 11,311 shares of the firm’s stock in a transaction on Tuesday, June 23rd. The stock was sold at an average price of $0.90, for a total value of $10,179.90. Following the sale, the chief executive officer directly owned 3,669,802 shares in the company, valued at $3,302,821.80. The trade was a 0.31% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Jeffrey Alan Hawkins also recently made the following trade(s):

• On Monday, June 22nd, Jeffrey Alan Hawkins sold 11,310 shares of Quantum-Si stock. The stock was sold at an average price of $0.96, for a total value of $10,857.60.
• On Monday, April 20th, Jeffrey Alan Hawkins sold 83,712 shares of Quantum-Si stock. The stock was sold at an average price of $1.01, for a total value of $84,549.12.

Quantum-Si Price Performance

NASDAQ QSI opened at $0.86 on Friday. The firm has a market cap of $186.69 million, a P/E ratio of -1.68 and a beta of 3.18. The stock’s 50-day moving average is $0.99 and its 200-day moving average is $1.03. Quantum-Si Incorporated has a one year low of $0.69 and a one year high of $3.10.

Quantum-Si (NASDAQ:QSI) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $0.02. Quantum-Si had a negative return on equity of 47.35% and a negative net margin of 5,605.88%.The business had revenue of $0.26 million during the quarter, compared to analyst estimates of $0.30 million. Equities analysts anticipate that Quantum-Si Incorporated will post -0.49 EPS for the current year.

Institutional Investors Weigh In On Quantum-Si

Institutional investors have recently bought and sold shares of the company. Millennium Management LLC acquired a new position in Quantum-Si during the 1st quarter worth approximately $4,721,000. State Street Corp raised its holdings in shares of Quantum-Si by 26.5% in the fourth quarter. State Street Corp now owns 3,562,721 shares of the company’s stock valued at $3,919,000 after purchasing an additional 745,231 shares during the last quarter. Squarepoint Ops LLC bought a new stake in shares of Quantum-Si in the third quarter worth $865,000. Bank of America Corp DE lifted its position in shares of Quantum-Si by 426.6% in the second quarter. Bank of America Corp DE now owns 465,999 shares of the company’s stock worth $913,000 after purchasing an additional 377,504 shares in the last quarter. Finally, Geode Capital Management LLC boosted its holdings in Quantum-Si by 9.8% during the fourth quarter. Geode Capital Management LLC now owns 4,114,375 shares of the company’s stock worth $4,527,000 after purchasing an additional 367,206 shares during the last quarter. Institutional investors own 39.90% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on QSI. Weiss Ratings reissued a “sell (d-)” rating on shares of Quantum-Si in a research report on Friday, March 27th. Canaccord Genuity Group cut their price objective on shares of Quantum-Si from $1.50 to $1.00 and set a “hold” rating on the stock in a research report on Wednesday, March 4th. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Reduce” and a consensus price target of $1.00.

Quantum-Si Company Profile

Quantum-Si Inc is a life sciences instrumentation company headquartered in Guilford, Connecticut, developing next-generation proteomics solutions based on semiconductor sequencing technology. The company’s core offering centers on a proprietary single-molecule protein sequencing platform that uses a silicon-based sensor chip to convert protein data into digital signals. This approach is designed to deliver high sensitivity, single-amino-acid resolution and deep proteome coverage while potentially reducing cost and complexity compared to traditional mass spectrometry methods.

Quantum-Si’s product roadmap includes the development and commercialization of an integrated system comprising instruments, consumable reagents and proprietary data analysis software.